人类的核受体 由 48 种转录因子组成。其中,10 种被视为孤核受体 (ONR),因为尚未确定天然配体,而 26 种以前是孤儿核受体,但在发现各自的天然配体后,现在被标记为已采用核受体。尽管已采用核受体与内源性配体结合,但核受体功能是否受配体调节仍不清楚。其余 12 种核受体使用内分泌激素作为内源性配体,被归类为内分泌核受体。配体与核受体结合通常会诱导构象变化,使核受体能够与基因组中的靶 DNA 基序(称为核受体反应元件 (NRRE))结合,并募集调节靶基因转录的共调节蛋白。由于核受体可能受配体调节或可用作药物,因此它们是使用小分子化合物的有吸引力的治疗靶点。孤儿核受体为揭示影响人类健康的新型调节系统提供了独特的资源,也为多种人类疾病提供了药物靶点。核受体配体已用于多种重要的治疗领域,例如乳腺癌、皮肤病和糖尿病。
Nuclear receptors consist of 48 transcription factors in humans. Of these, 10 are considered orphan nuclear receptors (ONRs) because the natural ligand has not yet been identified, while 26 are former orphans but are now labeled as adopted NRs after the discovery of their respective natural ligands. Although adopted NRs bind endogenous ligands, it remains unclear whether the NR function is ligand-regulated. The remaining 12 NRs employ endocrine hormones as endogenous ligands and are classified as endocrine NRs. Ligand binding to NRs typically induce a conformational change that enable binding of NRs to target DNA motifs across the genome called nuclear receptor response elements (NRREs) and recruitment of co-regulator proteins that modulate transcription of target genes. Because ONRs could potentially be ligand-regulated or druggable, they are attractive therapeutic targets using small molecule compounds. Orphan nuclear receptors provide a unique resource for uncovering novel regulatory systems that impact human health and also provide drug targets for a variety of human diseases. Ligands of nuclear receptors have been used in several important therapeutic areas, such as breast cancers, skin disorders and diabetes[1][2].
(+)-LRH-1 modulator-1 是 LRH-1 modulator-1 的一种立体异构体,而 LRH-1 modulator-1 (compound 6N) 是一种有效的 LRH-1(肝受体同源物-1)调节剂/激动剂,在肠道类器官中具有抗炎作用,可诱导抗炎细胞因子 IL-10 并降低炎症细胞因子 IL-1b 和 TNFa。
BMH-9(Compound Z54)是核受体亚家族2、F组成员6(NR2F6,又称核孤儿受体Ear2)的调节剂,作为p53信号通路的激活剂可抑制人类癌细胞增殖,并在NOD-SCID小鼠模型中表现出抗肿瘤活性。
NR2F6 modulator-2 (Compound I) 是一种靶向自抑制性孤儿核受体 NR2F6(Nuclear Receptor subfamily 2 group F member 6)的调节剂,能抑制生物 NSD1 肽的募集,其 IC50 相当于 2 当量的 NR2F6,可用于癌症和免疫学研究。
TLX agonist 1(ccrp2)是一种孤核受体 tailless(TLX,NR2E1)调节剂(EC50=1 μM;Kd=650 nM),可增强 TLX 的转录抑制活性。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号